# TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

> **NCT06125522** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 11 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** vepdegestrant
- **DRUG:** Samuraciclib

## Key facts

- **NCT ID:** NCT06125522
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06125522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06125522, "TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06125522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*